1. Home
  2. TRX vs ADAG Comparison

TRX vs ADAG Comparison

Compare TRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$1.29

Market Cap

383.1M

Sector

N/A

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$2.85

Market Cap

222.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
ADAG
Founded
1990
2011
Country
Canada
China
Employees
N/A
128
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.1M
222.2M
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
TRX
ADAG
Price
$1.29
$2.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$1.70
$8.25
AVG Volume (30 Days)
3.1M
197.3K
Earning Date
04-15-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$84.84
N/A
Revenue Next Year
$96.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.44
52 Week High
$2.80
$4.85

Technical Indicators

Market Signals
Indicator
TRX
ADAG
Relative Strength Index (RSI) 58.74 33.30
Support Level $1.07 $2.78
Resistance Level $2.00 $3.19
Average True Range (ATR) 0.08 0.27
MACD 0.01 -0.04
Stochastic Oscillator 61.76 0.00

Price Performance

Historical Comparison
TRX
ADAG

About TRX TRX Gold Corporation

TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: